Review
Copyright ©The Author(s) 2018.
World J Gastroenterol. Aug 21, 2018; 24(31): 3500-3512
Published online Aug 21, 2018. doi: 10.3748/wjg.v24.i31.3500
Table 1 Immunometabolic therapies for cancers
TargetsAgentsMechanismsDevelopments
PKM2DASA, TEPP46Inhibition of HIF1αPreclinical
HIF1αPX-478, RO7070179, EZN-2968Inhibition of HIF1αPhase 1
PTENVO-Ohpic, SF1670Inhibition of PI3KPreclinical
PDKDichloroacetateInhibition of glycolysisPhase 2
GLUT1RitonavirInhibition of glycolysisFDA-Approved
LDHGossypol (AT-101), FX11, GalloflavinInhibition of glycolysisPhase 3
CPT1AEtomoxirInhibition of FAOPreclinical
CTLA-4IpilimumabCheckpoint blockade; Inhibition of FAOFDA-Approved
PD-1/PD-L1Nivolumab, Pembrolizumab, AtezolizumabCheckpoint blockade; Inhibition of FAOFDA-Approved
AMPKMetforminIncreased FAO; Inhibition of Complex I; Decreased mitochondrial ROSFDA-Approved
mTORTemsirolimus, EverolimusInhibition of HIF-1α translationFDA-Approved
IDOEpacadostatRegulation of tryptophan metabolism; Inhibition of mTORC1FDA-Approved
IDH1/2 mutationsIvosidenib (AG-120), IDH305, AG-881, DS-1001bInhibition of 2-HG productionPhase 3
FGFRRegorafenib, Sunitinib, TAS120Inhibition multi-targeted kinasePhase 2
iNOSL-NMMA, 1400WInhibition of NO productionPhase 2
FOXP3P60suppress NF-κB and NFATPreclinical